Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2644–2645. doi: 10.1128/aac.40.11.2644

Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex.

L M Shah 1, M S DeStefano 1, M H Cynamon 1
PMCID: PMC163591  PMID: 8913480

Abstract

WR99210, a dihydrofolate reductase inhibitor, has promising in vitro activity against Mycobacterium avium complex (MAC). The in vitro activities of WR99210 alone and in combination with a fixed concentration of dapsone (0.5 microgram/ml) were evaluated against 35 clinical MAC isolates by a broth dilution method. The MIC at which 50% of isolates were inhibited (MIC50) and MIC90 of WR99210 alone were 2 and 8 micrograms/ml, respectively. The MIC50 and MIC90 of WR99210 in combination with dapsone were 0.25 and 4 micrograms/ml, respectively. Overall, 75% of the MAC isolates displayed enhanced susceptibility to the combination.

Full Text

The Full Text of this article is available as a PDF (162.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang H. R., Arsenijevic D., Comte R., Polak A., Then R. L., Pechère J. C. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother. 1994 Aug;38(8):1803–1807. doi: 10.1128/aac.38.8.1803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Edstein M. D., Veenendaal J. R., Rieckmann K. H. Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. Chemotherapy. 1990;36(3):169–176. doi: 10.1159/000238763. [DOI] [PubMed] [Google Scholar]
  3. Gallant J. E., Moore R. D., Chaisson R. E. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994 Jun 1;120(11):932–944. doi: 10.7326/0003-4819-120-11-199406010-00006. [DOI] [PubMed] [Google Scholar]
  4. Meyer S. C., Majumder S. K., Cynamon M. H. In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex. Antimicrob Agents Chemother. 1995 Aug;39(8):1862–1863. doi: 10.1128/aac.39.8.1862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Seydel J. K. In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and mycobacteria. J Chemother. 1993 Dec;5(6):422–429. [PubMed] [Google Scholar]
  6. Shepard C. C., McRae D. H., Habas J. A. Sensitivity of Mycobacterium leprae to low levels of 4,4'-diaminodiphenyl sulfone. Proc Soc Exp Biol Med. 1966 Jul;122(3):893–896. doi: 10.3181/00379727-122-31282. [DOI] [PubMed] [Google Scholar]
  7. Voeller D., Kovacs J., Andrawis V., Chu E., Masur H., Allegra C. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). J Infect Dis. 1994 Feb;169(2):456–459. doi: 10.1093/infdis/169.2.456. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES